Healthcare problem: Pharma

++ All booklets now selling at 70% discount and fully available for free through the KDP unlimited circuit. Get them while it lasts!

Tailored content can be provided upon request. Submit your technical specification through the contact form in the About page at and get your quote.

Literature Review: Pharma problem for Healthcare

This “Ten Problems for Healthcare in the 2020s” booklet identifies ten relevant areas from very recent contributions put forward at academic level in the form journal articles, conference proceedings and students’ theses. Ten freely accessible internet references have been selected for each area and direct links are provided at the end of each chapter for own consultation. Our selected references do not intend to mirror ranking indexes nor establish novel classifications. On the contrary, they are meant to represent peer-reviewed, diverse and scientifically-sound case studies for vertical dissemination aimed at non-specialist readers. They will also be able to scoop even more references through the bibliography that is reported at the end of each selected reference.

Without further ado, these are the ten problems that we are going to introduce in this booklet:

  1. delivery,
  2. access,
  3. economics,
  4. digital,
  5. artificial intelligence,
  6. pharma,
  7. regulation,
  8. special needs,
  9. wellbeing,
  10. workforce.

Each problem has its own dedicated chapter made of an introductory section, a short presentation of the ten selected references and a conclusions section.

The final chapter of this booklet will report the conclusions from each chapter again in order to provide a complete executive summary.

6 Pharma

THE PROBLEM — The pharmaceutical industry heads the world ranking in total Research and Development investment and it is one of the few sectors still growing. Pharmaceutical innovation has improved the health and quality of life of patients. Moving from batch to continuous chemical processing and cheminformatics is now an important goal.

CASE STUDIES — … buy this booklet from Amazon …

CONCLUSIONS — The approval of a new drug by the corresponding agencies involves many variables that are difficult to predict. The aggregate use of new drugs can generate net savings to the healthcare system and to society, as they may release both healthcare and non-healthcare resources for alternative uses. Large pharma firms financially support R&D consortia, in part, because their value creation activities benefit members without disrupting the value capture or other aspects of the incumbent industry structure. When a drug patent expires, a traditional price competition ensues between the patent-holder and the generic manufacturer, with the patent-holder being seldom economically better-off. The key advantages of continuous flow manufacture include faster and safer reactions which can be more environmentally friendly. Although great strides have been made in the handling and analysis of biological and pharmacological data, more must be done to link the data to biological pathways. Wider changes in dispensing processes may have unintended consequences on other aspects of the healthcare system. Comparative effectiveness and cost effectiveness of drugs for use by patients in Ireland must be formally assessed. Counterfeit pharmaceuticals are an actively developing health and economic threat worldwide. Pharmaceutical wholesalers in South Africa cannot use price to compete in the market and must find a different competitive edge.

TEN FREE REFERENCES FROM THE INTERNET — … buy this booklet from Amazon …

“Ten Problems for Healthcare in the 2020s” booklet for Amazon Kindle, 2020; click on the cover to go to the dedicated Amazon listing page

By TenProblems

Literature Reviews for Inquisitive Minds